Multiple federal health agencies have stopped releasing some key health information — including updates on some outbreak investigations — amid a department-wide communications “pause” ordered by the ...
Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...